Rykindo is an extended release microspheres injection developed by Luye Pharma on its world-leading microsphere technology platform and represents an innovative new therapy for the treatment of schizophrenia. It is the first innovative microsphere formulation independently developed and owned by a Chinese company, including all related intellectual property, and is currently undergoing global registration. It is also China's first independently developed second-generation long-acting injectable antipsychotic. The launch of Rykindo® brings new hope for societal reintegration to around ten million schizophrenia patients in China.

March 27,2021